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2. Aim 
• This study aims to investigate the relative risk of SPCs in cancer survivors in Switzerland 
combining data from all Swiss cantonal cancer registries with at least 15 years of consecutive 
incidence data. 
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3. Methods 
Data source 
• This study used population-based cancer registry data from nine Swiss cantonal registries 
(incidence years 1981-2009) with a minimum survival of 6 months and a potential follow-up until 
the end of 2014 allowing a minimum of five years after initial diagnosis to ascertain the 
occurrence of a SPC (Ninitial cancers=310,113 ,NSPCs=33,793) 
Second primary tumour 
• A second primary tumour was defined as first subsequent primary cancer occurring at least 6 
months after the first cancer. The definition of primary cancers followed the rules defined by the 
IACR/IARC. 
Statistical analyses 
• Incomplete or missing follow-up was addressed using multiple imputation with 25 imputations.  
• The risk of second primary cancers was quantified using standardized incidence ratios (SIRs) for 
risk comparison with the general population.  
5. Novelty and Impact 
• This is the first comprehensive investigation of SPC risks in Switzerland combining data from all 
longstanding Swiss cantonal cancer registries.  
• Swiss cancer survivors have an increased risk of developing a SPC with the notable exception of 
patients with prostate cancer, female breast cancer and pancreatic  cancer. 
• Overall, the relative risk of SPCs is especially high in patients first diagnosed at younger ages (<50 
years) and patients surviving 10 years or more. 
• Overall, the relative risk of SPCs is similar for males and females. 
• Cancer patients should remain under continued surveillance not only for recurrent cancers but also 
for new primary cancers. 
1. Background 
• Currently, more people are living with a history of cancer than ever before and this increasing 
trend is likely to continue: one of the consequences of surviving cancer is the risk of being 
diagnosed with a second cancer.  
• Previous studies showed that cancer survivors have an increased risk for being diagnosed with a 
second primary cancer (SPC) [1-4]. 
• The only systematic investigation of SPC risks in Switzerland is outdated and based on data from 
a single canton cancer registry covering less than 10% of the Swiss population [5]. 
First primary cancer 0-49 years 50-64 years 65+ years 
        O    SIR 95% CI          O SIR 95% CI             O SIR 95% CI 
Oral Cavity & Pharynx 403 6.61 (5.94-7.28) 1103 3.76 (3.54-3.99) 665 2.05 (1.89-2.21) 
Oesophagus 30 8.03 (4.80-11.25) 118 2.89 (2.33-3.44) 96 1.57 (1.24-1.91) 
Stomach 49 1.79 (1.24-2.34) 205 1.43 (1.22-1.63) 317 1.09 (0.96-1.21) 
Colorectal 251 1.81 (1.58-2.04) 1376 1.27 (1.20-1.34) 2814 1.09 (1.05-1.13) 
Liver 17 5.39 (2.40-8.37) 44 1.50 (1.01-1.99) 62 1.16 (0.85-1.47) 
Pancreas 4 1.14 (0.00-2.65) 37 1.61 (1.03-2.18) 51 0.97 (0.68-1.26) 
Larynx 91 3.56 (2.78-4.35) 470 2.94 (2.66-3.21) 332 1.88 (1.67-2.09) 
Lung 120 3.00 (2.43-3.57) 671 1.98 (1.82-2.13) 769 1.44 (1.34-1.55) 
Skin Melanoma 386 1.33 (1.19-1.46) 807 1.21 (1.12-1.29) 1083 1.20 (1.12-1.27) 
Breast female 748 0.98 (0.90-1.05) 2041 1.01 (0.96-1.05) 2356 0.96 (0.92-1.00) 
Cervix Uteri 169 1.63 (1.37-1.88) 163 1.75 (1.47-2.04) 126 1.43 (1.17-1.70) 
Corpus Uteri & NOS 90 1.66 (1.29-2.03) 581 1.26 (1.16-1.37) 650 1.13 (1.04-1.22) 
Ovary 74 1.56 (1.17-1.94) 155 1.30 (1.08-1.51) 138 1.11 (0.92-1.31) 
Prostate 17 1.15 (0.51-1.79) 1269 0.77 (0.72-0.81) 4352 0.75 (0.73-0.77) 
Testis 239 1.39 (1.21-1.58) 86 1.34 (1.03-1.64) 22 1.75 (0.91-2.59) 
Kidney 71 1.69 (1.27-2.12) 331 1.38 (1.23-1.54) 464 1.25 (1.14-1.37) 
Bladder 68 2.10 (1.56-2.64) 588 1.67 (1.53-1.81) 1087 1.39 (1.31-1.48) 
Brain & Central Nerves 51 2.05 (1.43-2.66) 43 1.24 (0.83-1.65) 19 0.99 (0.48-1.50) 
Thyroid 152 1.49 (1.24-1.74) 191 1.48 (1.26-1.70) 158 1.31 (1.09-1.53) 
Hodgkin Lymphoma 174 3.31 (2.79-3.83) 91 2.27 (1.77-2.77) 58 1.77 (1.27-2.26) 
Non Hodgkin Lymphoma 162 1.92 (1.61-2.23) 472 1.40 (1.27-1.53) 689 1.30 (1.20-1.40) 
Multiple Myeloma 14 1.30 (0.50-2.11) 85 1.14 (0.88-1.40) 194 1.13 (0.96-1.30) 
Leukaemia 96 2.43 (1.91-2.95) 334 1.70 (1.51-1.89) 528 1.40 (1.28-1.52) 
  
All Cancers  3783 1.68 (1.62-1.73) 11920 1.32 (1.30-1.35) 18090 1.05 (1.04-1.07) 
First primary cancer 6 month - 1 year 1 year – 5 years 5 years - 10 years 10+ years 
      O  SIR 95% CI        O SIR 95% CI        O SIR 95% CI O SIR 95% CI 
Oral Cavity & Pharynx 166 3.28 (2.75-3.80) 971 3.54 (3.31-3.77) 636 3.18 (2.93-3.44) 398 2.59 (2.33-2.86) 
Oesophagus 30 1.78 (1.06-2.49) 131 2.51 (2.06-2.97) 47 1.97 (1.35-2.59) 36 2.82 (1.79-3.84) 
Stomach 46 0.98 (0.67-1.30) 205 1.09 (0.93-1.25) 163 1.34 (1.12-1.55) 157 1.48 (1.24-1.73) 
Colorectal 280 1.08 (0.95-1.21) 1671 1.10 (1.04-1.15) 1332 1.19 (1.13-1.26) 1158 1.29 (1.21-1.36) 
Liver 20 1.26 (0.62-1.89) 58 1.19 (0.85-1.52) 28 1.77 (1.03-2.52) 17 3.13 (1.40-4.87) 
Pancreas 18 0.87 (0.40-1.33) 45 1.15 (0.78-1.52) 16 1.30 (0.56-2.05) 13 1.86 (0.66-3.06) 
Larynx 53 2.61 (1.84-3.37) 361 2.77 (2.47-3.06) 256 2.34 (2.04-2.63) 223 2.19 (1.89-2.50) 
Lung 201 1.47 (1.26-1.69) 642 1.53 (1.41-1.65) 411 1.92 (1.73-2.11) 306 2.15 (1.90-2.40) 
Skin Melanoma 113 1.28 (1.03-1.52) 709 1.12 (1.04-1.21) 687 1.22 (1.13-1.32) 767 1.32 (1.22-1.41) 
Breast female 197 0.78 (0.67-0.90) 1532 0.85 (0.80-0.89) 1632 1.01 (0.96-1.06) 1784 1.14 (1.08-1.19) 
Cervix Uteri 16 1.31 (0.56-2.06) 108 1.45 (1.16-1.74) 124 1.69 (1.38-2.01) 210 1.68 (1.44-1.92) 
Corpus Uteri & NOS 46 0.95 (0.65-1.25) 386 1.15 (1.03-1.27) 359 1.12 (1.00-1.24) 530 1.37 (1.25-1.49) 
Ovary 20 0.86 (0.43-1.30) 105 0.93 (0.74-1.12) 102 1.36 (1.08-1.65) 140 1.75 (1.44-2.05) 
Prostate 348 0.68 (0.61-0.76) 2423 0.71 (0.68-0.74) 1868 0.76 (0.72-0.79) 999 0.91 (0.85-0.97) 
Testis 7 1.55 (0.10-3.00) 63 1.60 (1.17-2.03) 70 1.33 (0.99-1.67) 207 1.36 (1.17-1.56) 
Kidney 65 1.64 (1.21-2.07) 318 1.27 (1.12-1.41) 243 1.23 (1.07-1.39) 240 1.47 (1.27-1.66) 
Bladder 150 1.77 (1.47-2.06) 679 1.43 (1.32-1.54) 483 1.43 (1.30-1.56) 431 1.62 (1.46-1.78) 
Brain & Central Nerves 15 1.52 (0.62-2.43) 38 1.27 (0.82-1.72) 25 1.26 (0.70-1.82) 35 1.83 (1.15-2.50) 
Thyroid 20 1.46 (0.73-2.20) 151 1.46 (1.22-1.71) 125 1.20 (0.98-1.42) 205 1.57 (1.34-1.80) 
Hodgkin Lymphoma 8 1.53 (0.21-2.85) 99 2.89 (2.28-3.49) 70 2.09 (1.56-2.62) 146 2.78 (2.30-3.26) 
Non Hodgkin Lymphoma 81 1.26 (0.97-1.56) 494 1.27 (1.16-1.39) 401 1.40 (1.26-1.54) 347 1.62 (1.44-1.79) 
Multiple Myeloma 21 0.75 (0.38-1.12) 145 1.04 (0.86-1.21) 91 1.44 (1.13-1.76) 36 1.38 (0.88-1.88) 
Leukaemia 51 1.14 (0.80-1.48) 381 1.43 (1.29-1.58) 308 1.68 (1.49-1.88) 218 1.83 (1.57-2.08) 
  
All Cancers  2098 1.10 (1.06-1.15) 12532 1.11 (1.09-1.13) 10011 1.17 (1.15-1.19) 9152 1.36 (1.34-1.39) 
Fig. 1: Relative risk of second primary cancers by first primary cancer and sex 
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